BioLargo, Inc. · OTC:BLGO
BioLargo — Shareholder Meeting (June 2021)
31 slides from BioLargo's shareholder meeting presentation, Jun 15, 2021
Slide 1: BioLargo Annual Meeting of Stockholders
2021-06-14 b BioLargo We Make Life Better Annual Meernee of Stockholders June 15, 2021 OTCOB:BLGO Westminster, CA non factors including bu mt Sate veo auton pice campeon aang sop pring sie ppeaon dns, eaten ant wear 1
Slide 2: We Make Life Better
We Make Life Better r(' BioLargo (Oy BioLargo OsioLergc Water (+)
Slide 3: The Hardest Work is Done
The Hardest Work is Done + 80+ grants, 20+ patents + Built credibility and standing for our technologies and talent + Proved commercial viability + Created big opportunities: + PFAS treatment + Formed partnerships like Garratt- Callahan & Odin / BKT + Mineral extraction + Retail initiatives
Slide 4: Revenue and Debt
2021-06-14 Revenue and Debt 000K $900k $600k $700k $400k $500k $c00K 300% $200K $100k $2.4 M revenue jenerated 2020 . Quarterly Revenue u Debt* Comparison 1 G2 G3 a4 a1 a2 as a4 at a2 as a4 oF o2 as a4 at a2 an 2018 209 2m 1 G2 03 04 OF 02 G2 G% at G2 G3 04 OI a? 2 G4 OI Now zon re aa na zon ™BioLar
Slide 5: Financial condition improving
2021-06-14 Financial condition improving » Debt reduced + Revenue increasing + Net loss decreasing + Net shareholder equity increasing * Moving toward conditions necessary for up-list
Slide 6: What can move the needle?
2021-06-14 the needle? _— (Cciean dy AOS Mineral extraction. What can move gear CALLAHAN
Slide 7: BioLargo Water
2021-06-14 O BioLargo Water CONVEENVIRONMENTAL
Slide 8: PFAS
PFAS PFAS considered “contaminant of the decade” Regulatory action by Federal government accelerating Over 200 heavily affected military sites in the US 2,337 sites in 49 states and growing Industry experts agree market could exceed $80 billion/year in ~5-10 years
Slide 9: PFAS Treatment Technology
2021-06-14 PFAS Treatment Sac © seme Technology + First commercial pilots planned in 2021 + 3”_party validated by industry experts + The SUSTAINABLE option for PFAS treatment
Slide 10: Organic Growth
2021-06-14 Organic Growth + New West Coast Office + Fence to Fence for Seven USAF Bases + Multiple New Patents Pending + >$2 million backlog + Expanding Client Base
Slide 11: Satisfied Customers and Clients
2021-06-14 Satisfied Customers and Clients Citizens Gas DO E ENREMA Union Carbide Proton Power HAVCO. Schlegel TSCAi Moss Landiny usamy Picatinny Arsenal Major Waste Handlers Lamb Weston New Major Commercial Project Wins for BLEST (>$1.2m) Notified of contract awards in past 2 weeks + FEED design fo
Slide 12: Deals in negotiation
Deals in negotiation Commercial Industrial Park - Pilot Scale Magnesium Carbonate Production Plant from Waste Materials. Agriculture ~ Application of BioLargo Technologies to Agriculture Sector through California Ag Tech company. Renewables - Production of Electrical Power Storage Batteries using ne
Slide 13: BioLargo Water
2021-06-14 (6) BioLargo Water CONVEENVIRONMENTAL
Slide 14: Industrial Odor and VOC Eliminator
2021-06-14 Industrial Odor and VOC Eliminator System Design, Build and Install Experts * Eliminates odors - no masking * Non-pesticide, non-toxic * Saves customers 25-50% * Design, Build, installation, maintenance services + Leading waste companies under national contract
Slide 15: Industrial Air Quality Control Solutions
2021-06-14 Cyeays ne Industrial Air Quality Control Solutions Wastewater EcoMist Mobile air quality
Slide 16: Transfer stations, Landfills
2021-06-14 Transfer stations, § Landfills materials recovery, reeycting } National Waste Handling Contracts & Municipalities Cannabis & Hemp
Slide 17: BKT / Odin
2021-06-14 BKT / Odin South Korean Joint Venture Future Opportunities in negotiation through partnerships + We will make public disclosure as these deals unfold + Multiple private label customer deals + Leverage our top-performing product
Slide 18: Engineering, Science & Technologies
2021-06-14 \G} BioLargo Engineering, Science & Technologies (6) BioLargo Water CONVEENVIRONMENTAL
Slide 19: Advanced Oxidation System (AOS)
2021-06-14 Advanced Oxidation System (AOS) Energy-Efficient Water Treatment A TECHNICAL LEAP FORWARD Low cost - Energy Efficient - Extreme Performance Exceptional performance vs. micropollutants
Slide 20: AOS Commercial Design
AOS Commercial Design Modular, scalable Spiral design - increased scalability New prototype + 200 L/min reactor unit + Pictured unit has 2 reactors + Larger units available 4-reactor version could treat municipal flow rates Small footprint
Slide 21: First Projects AOS
2021-06-14 First Projects <>AOS Disinfection: a commercial-scale trial at joultry farm in Alberta Papeete and Micropollutant Removal: Municipal wastewater pilot ongoing Montreal Canada.
Slide 22: Exploring Micropollutant treatment partners in Europe
2021-06-14 Exploring Micropollutant treatment partners in Europe + Wide range of chemicals including pharmaceuticals and pesticides. + Micropollutant discharge regulations have started to come into effect across Europe + End-users looking for solutions. + Markets in industrial wastewater and municip
Slide 23: What's Next for BioLargo Water?
commercialize and monetize the AOS What's Next for BioLargo Water? Identify and negotiate strategic partnerships around the globe to AOS for micropollutants More publications and marketing Wastewater treatment and macro- pollutant femexel project at Pine Creek Albert AOS for ita water project (fundi
Slide 24: CONVEENVIRONMENTAL
2021-06-14 CONVEENVIRONMENTAL
Slide 25: The Clyra Advantage
2021-06-14 THE CLYRADVANTAGE Ciyra™ Antimicrobial Products SkinDise™ Infection Prevention & Centro ‘Advanced Wound Heating @©cwre Clyra Medical Technologies:
Slide 26: Clyra Antimicrobial Products
2021-06-14 (+) cLYRA Clyra™ Antimicrobial Products . + Adifferentiated game-changing antimicrobial ‘The result of novel, patent-pending Copper/ladine platform techology ‘Establishes a new standard in Infection, Prevention & Control ‘+ FDA 510K) cleared for cleansing, erigation, and debridement of le
Slide 27: Clyra Antimicrobials - Market Opportunities
2021-06-14 Gowen Clyra Antimicrobials - Market Opportunities Total Joint Orthopedics 7M primary hipand kneesannually | *48M Surgeries annually 2% infection rate 2% infection rate Joint infections cost >S100K. ‘Lite toino change SSI Infection rates for over 4 decades, 155i cost $10-25K per treatment
Slide 28: bioclynse
bioclynse* Product Launch eeauRch _ GSS complete . Marketing material — Complete Process
Slide 29: Product launch timelines (assuming funding secured)
2021-06-14 Product launch timelines (assuming funding secured) Comparable valuations are significant Evaluating capital resources to fund Clyra $5+ million capital required to launch and grow sales aos was 2m0 woo wae WR Ano Rev & Primary 4& Reconstruction Dental ‘kinDise / Wound & Burn
Slide 30: Clyra Medical Technologies
2021-06-14 C CLYRA’ Medical Technologies Ini Steve Harrison CEO 949-350-4985
Slide 31: Contact BioLargo
2021-06-14 OTCGB: BLGO Contact: Dennis Calvert President & CEO BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 (888) 400-2863 dc@BioLargo.com www.BioLargo.com The BioLargo 6 BioLargo Family of Companies : eet ave ee pee per nema, ee aera eg nce Nets OpBiolarme ocwra